VVOS - Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada

• Vivos Therapeutics ( NASDAQ: VVOS ) entered into an exclusive distribution agreement with GM Instruments for the distribution of GM Instruments’ NR6 Rhinomanometer, the only FDA approved 4-phase rhinomanometer available in the U.S. used to calculate nasal airway resistance by measuring nasal flow and the pressure producing that flow.
• The objective measurement of nasal breathing can be an essential data point in determining the appropriate breathing and sleep issue treatment pathway as well as a predictor of potential Continuous Positive Airway Pressure (or CPAP) intolerance or other treatment failure.
• “With this new agreement, every U.S. or Canadian dentist who wishes to evaluate the breathing function of a patient will need to engage with Vivos for this diagnostic equipment. We expect this will provide Vivos an immediate new revenue stream as well as a substantial competitive advantage and opportunity to present Vivos’ proprietary oral appliance technology to a wider audience,” said Chairman and CEO, Kirk Huntsman.

For further details see: